Growth Ratio Summary

Growth Score : 10.00

Concord Biotech demonstrates strong growth across all key metrics, including revenue, operating profit, EPS, assets, and net income. This consistent growth indicates a robust business model, effective management strategies, and a favorable market position. The company is expanding its operations and profitability, positioning it well for future success and increased shareholder value.

Financial Ratio Summary

Financial Score : 8.00

The company showcases strong financial performance with high adjusted and cash earnings per share, along with a solid book value per share, reflecting good profitability and asset value. While the dividend per share is also healthy, the capital expenditures suggest potential inefficiencies in managing investments or a need for strategic capital allocation improvements.

Profitability Ratio Summary

Profitability Score : 10.00

Concord Biotech exhibits excellent profitability, with high gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. These metrics indicate efficient operations, effective capital utilization, and strong overall financial performance. The company generates substantial profits from its sales and investments, reflecting positively on its management and strategic decision-making.

Efficiency Ratio Summary

Efficiency Score : 2.67

The company's efficiency ratios show areas of concern. The fixed asset and capital turnover ratios are low, indicating inefficient use of assets to generate revenue. High days sales in inventory and receivable days suggest challenges in managing inventory and collecting receivables promptly. Improving asset utilization and working capital management could free up cash and improve overall financial performance.

Coverage Ratio Summary

Coverage Score : 10.00

Concord Biotech demonstrates excellent coverage ratios, with a very high interest coverage ratio indicating a strong ability to meet its interest obligations. A good equity dividend coverage ratio suggests that the company can comfortably cover its dividend payments to shareholders. These coverage ratios reflect the company's financial stability and ability to manage its financial obligations effectively.

Solvency Ratio Summary

Solvency Score : 10.00

Concord Biotech exhibits excellent solvency, with minimal debt relative to its equity and assets. This indicates a very strong financial structure and low risk of financial distress. The high equity ratio further supports the company's financial stability, ensuring long-term sustainability and resilience against economic downturns, reflecting a solid foundation for future growth and stability.

Liquidity Ratio Summary

Liquidity Score : 8.34

The company's liquidity position is strong, as reflected in its current and quick ratios, indicating a good ability to meet short-term obligations. However, the cash ratio is low, suggesting that the company holds a relatively small amount of cash compared to its current liabilities. The operating cash flow ratio indicates an adequate ability to cover current liabilities with operating cash flow. While the company has a good handle on their short term liabilities, having more cash on hand would be ideal.